

Efficacy of lamivudine for preventing hepatocellular carcinoma: a multicenter retrospective study of 2795 patients

Hepatology Research

32, 173-184

DOI: [10.1016/j.hepres.2005.02.006](https://doi.org/10.1016/j.hepres.2005.02.006)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Early liver cancer: concepts, diagnosis, and management. <i>International Journal of Clinical Oncology</i> , 2005, 10, 384-390.	1.0	6
2	Management of hepatocellular carcinoma in Japan. <i>Journal of Gastroenterology</i> , 2006, 41, 100-106.	2.3	38
3	Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. <i>Journal of Gastroenterology</i> , 2006, 41, 785-790.	2.3	69
4	Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C. <i>Journal of Medical Virology</i> , 2006, 78, 1276-1283.	2.5	40
5	Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. <i>Hepatology Research</i> , 2007, 37, 94-100.	1.8	87
6	Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. <i>Hepatology Research</i> , 2007, 37, 661-666.	1.8	73
7	Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine. <i>Journal of Medical Virology</i> , 2007, 79, 1472-1477.	2.5	17
8	Hepatocellular carcinoma development in cirrhosis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 161-173.	1.0	64
9	Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1929-1935.	1.4	112
10	Epidemiology of hepatocellular carcinoma in Japan. <i>Hepatology Research</i> , 2007, 37, S95-S100.	1.8	58
11	Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. <i>Journal of Gastroenterology</i> , 2007, 42, 368-374.	2.3	15
12	Nucleos(t)ide analogues for hepatitis B virus: Strategies for long-term success. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2008, 22, 1081-1092.	1.0	28
13	Successful treatment with lamivudine may correlate with reduction of serum ferritin levels in the patients with chronic hepatitis and liver cirrhosis type B. <i>Hepatology International</i> , 2008, 2, 382-387.	1.9	7
14	A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 794-803.	1.4	27
15	Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1067-1077.	1.9	338
16	Optimal duration of additional therapy after biochemical and virological responses to lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomized trial. <i>Hepatology Research</i> , 2008, 38, 954-959.	1.8	7
17	The case for combination antiviral therapy for chronic hepatitis B virus infection. <i>Lancet Infectious Diseases</i> , 2008, 8, 444-448.	4.6	7
18	Virological Response and Hepatocarcinogenesis in Lamivudine-Resistant Hepatitis B Virus Genotype C Patients Treated with Lamivudine plus Adefovir Dipivoxil. <i>Intervirology</i> , 2008, 51, 385-393.	1.2	13

#	ARTICLE	IF	CITATIONS
20	3. Chronic Hepatitis and Liver Cancer. The Journal of the Japanese Society of Internal Medicine, 2008, 97, 508-512.	0.0	1
21	Long Term Effects of Lamivudine and Adefovir dipivoxil in Chronic Hepatitis B Patients on the Development of Hepatocellular Carcinoma. Yeungnam University Journal of Medicine, 2008, 25, 1.	0.1	0
22	Hepatocellular Carcinoma in Keio Affiliated Hospitals " Diagnosis, Treatment, and Prognosis of this Disease ". Keio Journal of Medicine, 2009, 58, 161-175.	0.5	9
23	JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C. Acta Hepatologica Japonica, 2009, 50, 665-677.	0.0	0
24	Low hepatitis B virus core-related antigen is a predictor of absence in post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Acta Hepatologica Japonica, 2009, 50, 588-589.	0.0	0
25	The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. Journal of Gastroenterology, 2009, 44, 991-999.	2.3	95
26	Current treatment of chronic HBV infection: An Asian-Pacific perspective. Current Hepatitis Reports, 2009, 8, 154-160.	0.3	2
27	Prevention of hepatocellular carcinoma in hepatitis B virus infection. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1352-1357.	1.4	67
28	Hepatitis B virus DNA in patients with hepatitis B-related liver cirrhosis with or without hepatocellular carcinomas: a matched case-control study. Journal of Digestive Diseases, 2009, 10, 138-144.	0.7	8
29	Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver International, 2009, 29, 100-107.	1.9	181
30	Nucleotide Analogs for Patients with HBV-Related Hepatocellular Carcinoma Increase the Survival Rate through Improved Liver Function. Internal Medicine, 2009, 48, 11-17.	0.3	43
31	JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B. Acta Hepatologica Japonica, 2010, 51, 243-260.	0.0	0
32	Evolution of prognostic factors in hepatocellular carcinoma in Japan. Alimentary Pharmacology and Therapeutics, 2010, 31, 407-414.	1.9	20
33	Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 583-590.	1.4	69
34	Prevention of hepatocellular carcinoma. Annals of Hepatology, 2010, 9, 120-132.	0.6	14
35	Therapy with Nucleos(t)ide Analogues: Current Role in Dialysis Patients. International Journal of Artificial Organs, 2010, 33, 329-338.	0.7	12
36	Management of Hepatocellular Carcinoma: From Prevention to Molecular Targeted Therapy. Oncology, 2010, 78, 1-6.	0.9	17
37	Sensitive Assay for Quantification of Hepatitis B Virus Mutants by Use of a Minor Groove Binder Probe and Peptide Nucleic Acids. Journal of Clinical Microbiology, 2010, 48, 4487-4494.	1.8	9

#	ARTICLE	IF	CITATIONS
38	Does chemotherapy prevent HBV-related hepatocellular carcinoma? Pros. Digestive and Liver Disease, 2010, 42, S293-S297.	0.4	7
39	Does chemotherapy prevent HBV-related hepatocellular carcinoma? Cons. Digestive and Liver Disease, 2010, 42, S298-S301.	0.4	4
40	Hepatocellular carcinoma: a global view. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 448-458.	8.2	1,159
42	Risk assessment for the development of hepatocellular carcinoma: According to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. Journal of Hepatology, 2010, 53, 118-125.	1.8	114
43	Epidemiology and Management of Hepatocellular Carcinoma. Infectious Disease Clinics of North America, 2010, 24, 899-919.	1.9	166
44	Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2011, 9, 64-70.	2.4	216
45	Hepatocellular Carcinoma in 2011 and Beyond: From the Pathogenesis to Molecular Targeted Therapy. Oncology, 2011, 81, 1-10.	0.9	23
46	Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009. Hepatology Research, 2011, 41, 1-21.	1.8	24
47	Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatology Research, 2011, 41, 405-416.	1.8	39
48	Treatment of chronic hepatitis B: Evolution over two decades. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 138-143.	1.4	143
49	Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2011, 33, 1104-1112.	1.9	159
50	Long-Term Nucleos(t)ide Analogues Therapy for Adults With Chronic Hepatitis B reduces the Risk of Long-Term Complications: a meta-analysis. Virology Journal, 2011, 8, 72.	1.4	55
51	Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic hepatitis B patients whose initial tumor was successfully ablated. International Journal of Cancer, 2011, 128, 739-742.	2.3	18
52	Accelerated progression of hepatocellular carcinoma with cytokeratin 19 expression during treatment with lamivudine for hepatitis B virus-related liver cirrhosis. Scandinavian Journal of Gastroenterology, 2011, 46, 249-251.	0.6	5
53	Impact of Antiviral Therapy on the Survival of Patients After Major Hepatectomy for Hepatitis B Virus-Related Hepatocellular Carcinoma. Archives of Surgery, 2011, 146, 675.	2.3	102
54	Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. Oncology, 2011, 81, 41-49.	0.9	42
55	Prevalence and associations with hepatitis B and hepatitis C infection among HIV-infected adults in South Africa. International Journal of STD and AIDS, 2012, 23, e10-e13.	0.5	23
57	7. Cutting Edge of the Treatment for Viral Hepatitis. The Journal of the Japanese Society of Internal Medicine, 2012, 101, 131c-132a.	0.0	0

#	ARTICLE	IF	CITATIONS
58	Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection. <i>Hepatology Research</i> , 2012, 42, 22-32.	1.8	7
59	Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2012, 19, 685-696.	1.4	41
60	Causes of and Prevention Strategies for Hepatocellular Carcinoma. <i>Seminars in Oncology</i> , 2012, 39, 374-383.	0.8	49
61	A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression. <i>Oncology</i> , 2012, 82, 275-289.	0.9	35
62	Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. <i>Journal of Gastroenterology</i> , 2012, 47, 577-585.	2.3	58
63	Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2012, 42, 139-149.	1.8	57
64	Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2012, 19, 220-226.	1.0	28
65	Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. <i>Hepatology</i> , 2013, 57, 399-408.	3.6	183
66	Impact of therapy on the outcome of chronic hepatitis B. <i>Liver International</i> , 2013, 33, 111-115.	1.9	55
67	Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. <i>Hepatology</i> , 2013, 58, 98-107.	3.6	596
68	Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. <i>BMJ Open</i> , 2013, 3, e003265.	0.8	30
69	Hypovascular Nodules in Patients with Chronic Liver Disease: Risk Factors for Development of Hypervascular Hepatocellular Carcinoma. <i>Radiology</i> , 2013, 266, 480-490.	3.6	126
70	Long-term outcome of hepatitis B virus-related chronic hepatitis under protracted nucleos(t)ide analogues. <i>Journal of Viral Hepatitis</i> , 2013, 20, 502-509.	1.0	16
71	Antiviral therapy after curative resection for patients with hepatitis B-related hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2013, 100, 724-725.	0.1	1
72	Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. <i>World Journal of Gastroenterology</i> , 2013, 19, 6515.	1.4	38
73	Role of Anti-Viral Therapy on Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC). , 0, , .		0
74	Large Variations in Risk of Hepatocellular Carcinoma and Mortality in Treatment Na ⁺ -ve Hepatitis B Patients: Systematic Review with Meta-Analyses. <i>PLoS ONE</i> , 2014, 9, e107177.	1.1	37
75	Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy. <i>Liver Cancer</i> , 2014, 3, 41-52.	4.2	48

#	ARTICLE	IF	CITATIONS
76	Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2014, 44, 1-8.	1.8	59
77	A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation. <i>Cancer Medicine</i> , 2014, 3, 390-396.	1.3	35
78	Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1273-1278.	1.4	24
79	Time trends of clinical characteristics in hepatocellular carcinoma patients with chronic hepatitis B virus infection: A field survey between 2000 and 2012. <i>Molecular and Clinical Oncology</i> , 2014, 2, 927-934.	0.4	7
80	Higher efficacy of antiviral therapy after major hepatectomy in patients with hepatitis B virus-related hepatocellular carcinoma of less than 3cm. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1116-1124.	0.8	11
81	The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1262-1269.	1.9	53
82	JSH Guidelines for the Management of Hepatitis B Virus Infection. <i>Hepatology Research</i> , 2014, 44, 1-58.	1.8	142
83	A Deep-Sequencing Method Detects Drug-Resistant Mutations in the Hepatitis B Virus in Indonesians. <i>Intervirology</i> , 2014, 57, 384-392.	1.2	15
84	Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. <i>BMC Infectious Diseases</i> , 2014, 14, 439.	1.3	40
85	Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. <i>Gut</i> , 2014, 63, 1943-1950.	6.1	149
86	Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B—A Nationwide Cohort Study. <i>Gastroenterology</i> , 2014, 147, 143-151.e5.	0.6	267
87	A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. <i>Liver International</i> , 2015, 35, 2147-2154.	1.9	38
88	Hepatocellular carcinoma: From diagnosis to treatment. <i>World Journal of Hepatology</i> , 2015, 7, 1020.	0.8	137
89	Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-7.	0.7	5
90	Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. <i>World Journal of Hepatology</i> , 2015, 7, 1064.	0.8	46
91	Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1024-1031.	1.4	17
92	Prevention of Hepatocellular Carcinoma: Beyond Hepatitis B Vaccination. <i>Seminars in Oncology</i> , 2015, 42, 316-328.	0.8	16
93	Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. <i>Journal of Gastroenterology</i> , 2015, 50, 785-794.	2.3	30

#	ARTICLE	IF	CITATIONS
94	Improving clinical outcomes of chronic hepatitis B virus infection. Expert Review of Gastroenterology and Hepatology, 2015, 9, 141-154.	1.4	24
95	Antiviral Therapy Improves Postoperative Survival in Patients With Hepatocellular Carcinoma. Annals of Surgery, 2015, 261, 56-66.	2.1	178
96	Monotherapy for hepatitis B infection: a review of treatment options. Expert Review of Anti-Infective Therapy, 2015, 13, 1457-1468.	2.0	7
97	Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. Alimentary Pharmacology and Therapeutics, 2015, 41, 199-208.	1.9	51
98	KASL clinical practice guidelines: management of chronic hepatitis B. Clinical and Molecular Hepatology, 2016, 22, 18-75.	4.5	155
99	Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-11.	0.8	20
100	Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. Hepatology International, 2016, 10, 574-593.	1.9	18
101	Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology, 2016, 63, 284-306.	3.6	414
102	Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis. Hepatology Research, 2016, 46, 100-110.	1.8	39
103	Clinical Features and Clinician's Diagnostic Approach to Hepatocellular Carcinoma. , 2016, , 409-423.		0
104	Liver Fibrosis Reversion After Suppression of Hepatitis B Virus. Clinics in Liver Disease, 2016, 20, 667-679.	1.0	26
105	Comparison of collagen proportionate areas in liver fibrosis quantification between chronic hepatitis B and C. Medicine (United States), 2016, 95, e4736.	0.4	9
106	A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation. Medicine (United States), 2016, 95, e4832.	0.4	7
107	Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B. BMC Gastroenterology, 2016, 16, 38.	0.8	14
108	Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. Oncology, 2016, 90, 199-208.	0.9	9
109	The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 546-552.	1.4	19
110	Radiofrequency Ablation for Small Hepatocellular Carcinoma. , 2016, , .		4
111	Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. Hepatology International, 2016, 10, 320-327.	1.9	15

#	ARTICLE	IF	CITATIONS
112	Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Expert Review of Clinical Pharmacology, 2017, 10, 707-716.	1.3	31
113	Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis. Digestive Diseases and Sciences, 2017, 62, 808-816.	1.1	9
114	Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Review of Gastroenterology and Hepatology, 2017, 11, 1095-1104.	1.4	21
115	Hepatitis B core-related antigen: a strong indicator for cessation of nucleos(t)ide analog therapy in patients with chronic hepatitis B. Journal of Gastroenterology, 2017, 52, 127-128.	2.3	3
116	Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B. Current Medical Research and Opinion, 2017, 33, 495-504.	0.9	20
117	Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. Journal of Hepatology, 2018, 68, 526-549.	1.8	506
118	Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment. Hepatology Research, 2018, 48, E240-E251.	1.8	23
119	Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 262-279.	1.8	160
120	Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection. Infectious Agents and Cancer, 2018, 13, 19.	1.2	21
121	Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 442-449.	1.4	11
122	KASL clinical practice guidelines for management of chronic hepatitis B. Clinical and Molecular Hepatology, 2019, 25, 93-159.	4.5	171
123	Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 2811-2813.e1.	2.4	9
124	The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer, 2019, 19, 511.	1.1	53
125	Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. Journal of Viral Hepatitis, 2019, 26, 818-827.	1.0	40
126	Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk?. Digestive Diseases and Sciences, 2019, 64, 903-909.	1.1	20
127	Association between <i>HLA-DQA1/DRB1</i> polymorphism and development of hepatocellular carcinoma during entecavir treatment. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 937-946.	1.4	9
128	HIV-HBV and HIV-HCV Coinfection and Liver Cancer Development. Cancer Treatment and Research, 2019, 177, 231-250.	0.2	49
129	Lifestyle and Cancer Prevention. , 2020, , 337-374.e12.		3

#	ARTICLE	IF	CITATIONS
130	Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2423.	3.8	7
131	The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Public Health</i> , 2021, 9, 709220.	1.3	1
132	HIV and HBV and HIV and HCV Coinfection and Liver Cancer Development. <i>Cancer Treatment and Research</i> , 2007, , 241-252.	0.2	20
133	Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1277-1282.	0.8	2
134	The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area. <i>Medical Science Monitor</i> , 2011, 17, PH7-PH11.	0.5	16
135	Liver Cancer. , 2015, , 147-164.		6
136	Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy. <i>Oncotarget</i> , 2016, 7, 58553-58562.	0.8	3
137	Nucleoside analogs treatment delay the onset of hepatocellular carcinoma in patients with HBV-related cirrhosis. <i>Oncotarget</i> , 2017, 8, 96725-96731.	0.8	4
138	Adjuvant antiviral therapy for the prevention of hepatocellular carcinoma recurrence after liver resection: indicated for all patients with chronic hepatitis B?. <i>Annals of Translational Medicine</i> , 2018, 6, 397-397.	0.7	3
139	Guidelines for avoiding risks resulting from discontinuation of nucleos(t)ide analogues in patients with chronic hepatitis B (2012). <i>Acta Hepatologica Japonica</i> , 2012, 53, 237-242.	0.0	4
140	Guidelines for the management of hepatitis B virus infection. <i>Acta Hepatologica Japonica</i> , 2013, 54, 402-472.	0.0	4
141	Prevention of Hepatocellular Carcinoma. , 2009, , 36-61.		2
142	KASL Clinical Practice Guidelines: Management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2012, 18, 109.	4.5	143
144	Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. <i>World Journal of Gastroenterology</i> , 2006, 12, 7239.	1.4	74
145	Clinical features of hepatitis B virus-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2010, 16, 2463.	1.4	33
146	Lamivudine treatment enabling right hepatectomy for hepatocellular carcinoma in decompensated cirrhosis. <i>World Journal of Gastroenterology</i> , 2012, 18, 2586.	1.4	3
147	Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2012, 18, 6943.	1.4	6
148	Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2013, 19, 8861.	1.4	19

#	ARTICLE	IF	CITATIONS
149	Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence. <i>World Journal of Gastroenterology</i> , 2013, 19, 8895.	1.4	22
150	Then and now: The progress in hepatitis B treatment over the past 20 years. <i>World Journal of Gastroenterology</i> , 2014, 20, 401.	1.4	47
151	Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 8249.	1.4	24
152	Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. <i>World Journal of Gastroenterology</i> , 2015, 21, 13087.	1.4	5
153	Updated Treatment of Chronic Hepatitis B. <i>Korean Journal of Medicine</i> , 2019, 94, 252-262.	0.1	1
154	Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection. <i>World Journal of Hepatology</i> , 2014, 6, 652.	0.8	13
155	Current and future directions for treating hepatitis B virus infection. <i>World Journal of Hepatology</i> , 2015, 7, 1541.	0.8	26
156	Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 1742.	0.8	19
157	Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis. <i>World Journal of Hepatology</i> , 2015, 7, 2404.	0.8	10
158	Prevention by Lamivudine of Hepatocellular Carcinoma in Patients Infected with Hepatitis B Virus. <i>Gut and Liver</i> , 2007, 1, 151-158.	1.4	9
159	Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. <i>Gut and Liver</i> , 2019, 13, 197-205.	1.4	12
160	Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. <i>Cancer Biology and Medicine</i> , 2013, 10, 158-64.	1.4	48
161	A case of liver cirrhosis type B accompanied by hepatocellular carcinoma under lamivudine and adefovir treatment. <i>Acta Hepatologica Japonica</i> , 2007, 48, 429-438.	0.0	0
162	ç—†ã¾¼<â±âŠã€€è...«ç~â¾¼,6cmã*3cmã@é«~â^†âCE—âž<è,ç™èfžç™CEã@1â^†é™ã¾¼<. <i>Acta Hepatologica Japonica</i> , 2007, 48, 91-96.		
163	Hepatocellular Carcinoma Associated with Hepatitis B Virus. , 2009, , 235-257.		2
164	Antiviral therapy for hepatitis B virus-associated hepatic failure. , 2009, , 164-175.		3
165	Topics in the hepatitis viruses in the evaluation and promotion of health. <i>Health Evaluation and Promotion</i> , 2013, 40, 281-286.	0.0	0
166	Cancer Prevention, Screening, and Early Detection. , 2014, , 322-359.e12.		1

#	ARTICLE	IF	CITATIONS
167	Hepatitis Viruses: Hepatocellular Carcinoma. , 2014, , 785-804.		0
168	The Impact of Treating Chronic Liver Diseases on Hepatocellular Carcinoma Prevention. , 2012, , 229-246.		0
169	Management of chronic hepatitis B: New stopping rules. International Archive of Medicine, 0, , .	1.2	0
172	Prevention of Hepatocarcinogenesis in Liver Cirrhosis. , 2019, , 159-166.		0
173	Association analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients. Scientific Reports, 2021, 11, 21424.	1.6	4
174	Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Current Cancer Drug Targets, 2012, 12, 1129-59.	0.8	55
175	Adherence to Healthy Lifestyle and Liver cancer in Chinese: a prospective cohort study of 0.5 million people. British Journal of Cancer, 2022, 126, 815-821.	2.9	15
176	Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. Journal of Personalized Medicine, 2022, 12, 149.	1.1	14
178	Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. Antiviral Therapy, 2009, 14, 679-685.	0.6	9
179	Hepatitis B Virus Replication and Liver Disease Progression: The Impact of Antiviral Therapy. Antiviral Therapy, 2006, 11, 669-680.	0.6	109
180	Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy. Cancer Immunology, Immunotherapy, 0, , .	2.0	3